The ability of PRMT5 inhibitors to influence multiple cellular pathways and restore the function of tumor suppressors via demethylation may be attractive as a single agent in CLL to induce durable responses and prevent or delay acquired resistance, however, care must be taken evaluating this target in the clinical setting as PRMT5 is essential in normal hematopoiesis53. The gene discussed is PRMT5; the disease is neoplasm.